SML2499
TY-52156
≥98% (HPLC)
Synonym(s):
1-(4-Chlorophenylamino)-1-(4-chlorophenylhydrazono)-3,3-dimethyl-2-butanone, 1-(4-Chlorophenylhydrazono)-1-(4-chlorophenylamino)-3,3-dimethyl-2-butanone, N-(4-Chloroanilino)-N′-(4-chlorophenyl)-3,3-dimethyl-2-oxobutanimidamide, TY 52156, TY52156
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C18H19Cl2N3O
CAS Number:
Molecular Weight:
364.27
NACRES:
NA.77
UNSPSC Code:
12352200
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to very dark brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
CC(C)(C(/C(NC1=CC=C(C=C1)Cl)=N/NC2=CC=C(C=C2)Cl)=O)C
InChI
1S/C18H19Cl2N3O/c1-18(2,3)16(24)17(21-14-8-4-12(19)5-9-14)23-22-15-10-6-13(20)7-11-15/h4-11,22H,1-3H3,(H,21,23)
InChI key
XONRRGIRSGNWFP-UHFFFAOYSA-N
Biochem/physiol Actions
Orally active, potent and selective sphingosine 1-phosphate (S1P) receptor 3 (S1P3; S1PR3) antagonist with in vitro and in vivo efficacy.
TY-52156 is a potent sphingosine 1-phosphate (S1P) receptor 3 (S1P3; S1PR3) antagonist that selectively inhibits S1P-stimulated Ca2+ response in human S1P3-expressing cells (Ki = 110 nM) and Eu-GTP binding to S1P3-containing membranes over those of S1P1/2/4/5. TY-52156 inhibits S1P3-dependent signaling events in human coronary artery smooth muscle cells (1 μM), S1P3-dependent coronary flow decrease in perfused rat hearts, as well as S1P3-mediated acute mechanical pain in mice (10 nmol/20 μL/paw id.) and bradycardia in anesthetized rats (30 mg/kg TY-52156 p.o.) in vivo with good oral bioavailability (F = 70.9%; 1 mg/kg p.o. in rats).
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zhijing Zhao et al.
Experimental and therapeutic medicine, 15(6), 5007-5016 (2018-05-29)
Thyroid carcinoma is characterized by an aggressive behavior, lack of effective targeted therapies and a high rate of relapse. Sphingosine kinase 1 (SPHK1) has been reported to be a critical regulatory factor in the progression of thyroid carcinoma, but the
Xiao-Jing Sun et al.
Journal of cellular and molecular medicine, 22(3), 1769-1777 (2017-11-24)
Cumulating evidences suggested an important role of sphingosine-1-phosphate (S1P) and its receptors in regulating endothelial barrier integrity. Our previous study revealed that the circulating S1P levels and renal expression of S1PRs correlated with disease activity and renal damage in patients
Iuliia Filipenko et al.
Biochimica et biophysica acta, 1861(11), 1840-1851 (2016-09-13)
Breast cancer is one of the most common and devastating malignancies among women worldwide. Recent evidence suggests that malignant progression is also driven by processes involving the sphingolipid molecule sphingosine 1-phosphate (S1P) and its binding to cognate receptor subtypes on